STOCK TITAN

Alps Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Alps Group (Nasdaq: ALPS) regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Global Market. Nasdaq confirmed that the shares closed with a bid price of at least $1.00 for 10 consecutive business days, from November 9 through November 20, 2026, and closed the matter. The notification did not change trading in the shares.

The ordinary shares began trading on a 1-for-5 post-consolidation basis on November 9. Nasdaq staff had notified Alps on November 16 that the shares were subject to delisting because the company had not met the requirement by the November 11 compliance deadline.

Loading...
Loading translation...
1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointNasdaq minimum bid price compliance restored after 10 consecutive business days at or above $1.00; Nasdaq closed the matter.

Negative

  • None.

Key Figures

Minimum closing bid price: $1.00 per share Compliance period: 10 consecutive business days Share consolidation: 1-for-5
Minimum closing bid price
$1.00 per share
Nasdaq continued-listing requirement
Compliance period
10 consecutive business days
Closing bid was at least $1.00 per share from November 9 to November 20, 2026
Share consolidation
1-for-5
Ordinary shares began trading on a post-consolidation basis on November 9, 2026

Historical Context

1 past event · Latest: Oct 30
1 event
  1. Oct 30

    Share consolidation

    24h Move
    +0.0%

    Shareholders approved a 1-for-5 consolidation, effective November 9, before the reported compliance period.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

share consolidation
1 terms
share consolidation financial
"following the Company’s previously announced 1-for-5 share consolidation"
Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

KUALA LUMPUR, Malaysia, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

On May 19, 2026, the Company previously disclosed that, on May 15, 2026, the Company received a letter from Nasdaq notifying the Company that based on the closing bid price of the ordinary shares of the Company for the prior 30 consecutive business days, the Company was not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share.

On November 9, 2026, the Company’s ordinary shares began trading on a post-consolidation basis following the Company’s previously announced 1-for-5 share consolidation.

On November 16, 2026, the Company received a letter from the Nasdaq Listing Qualifications Staff stating that the Company had not regained compliance with Nasdaq Listing Rule 5450(a)(1), which required the listed ordinary shares to maintain a closing bid price of $1.00 per share for 10 consecutive business days, by November 11, 2026, the end of the applicable compliance period, and that the Staff had determined that the Company’s ordinary shares would be subject to delisting.

On November 20, 2026, the Nasdaq Listing Qualifications Staff notified the Company that the closing bid price of its ordinary shares had been $1.00 per share or greater for 10 consecutive business days, from November 9, 2026 to November 20, 2026. Accordingly, the Company has regained compliance with the minimum bid price requirement, and Nasdaq has confirmed that the matter is now closed.

The notification has no effect on the trading of the Company’s ordinary shares which continue to trade on The Nasdaq Global Market under the symbol “ALPS.”

About Alps Group Inc

Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.

Forward-Looking Statements

Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

Investor Relations Contact
Alps Group Inc
Investor Relations
Phone: +60 3-2163 1113
Email: investorrelations@alpsmedical.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Alps Group (ALPS) regain compliance with Nasdaq’s minimum bid price rule?

Alps Group’s ordinary shares maintained a closing bid price of $1.00 per share or greater for 10 consecutive business days, from November 9 through November 20, 2026. Nasdaq confirmed compliance with Rule 5450(a)(1) and closed the matter.

Keep reading